Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Rachel Rabinovitch

Concepts (341)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
56
2022
1862
3.740
 Why?
Mastectomy, Segmental
26
2022
76
1.980
 Why?
Brachytherapy
10
2019
103
1.440
 Why?
Hodgkin Disease
6
2020
120
1.330
 Why?
Lymphoma, Large B-Cell, Diffuse
6
2019
98
1.240
 Why?
Neoplasm Staging
34
2020
1167
1.220
 Why?
Mediastinal Neoplasms
3
2017
33
1.160
 Why?
Radiotherapy, Conformal
7
2016
68
0.990
 Why?
Carcinoma, Intraductal, Noninfiltrating
6
2022
49
0.940
 Why?
Neoplasm Recurrence, Local
12
2022
858
0.940
 Why?
Combined Modality Therapy
24
2022
1121
0.880
 Why?
Radiotherapy, Adjuvant
14
2017
182
0.870
 Why?
Antineoplastic Combined Chemotherapy Protocols
11
2021
1355
0.820
 Why?
Radiation Oncologists
1
2021
4
0.770
 Why?
Mastectomy
6
2017
99
0.710
 Why?
Carcinoma, Ductal, Breast
10
2016
76
0.630
 Why?
Lymphoma, Follicular
3
2019
35
0.620
 Why?
Radiotherapy Planning, Computer-Assisted
6
2020
117
0.600
 Why?
Mammography
5
2019
105
0.560
 Why?
Breast
3
2013
139
0.540
 Why?
Middle Aged
48
2021
26719
0.530
 Why?
Female
72
2022
59466
0.520
 Why?
SEER Program
7
2019
196
0.520
 Why?
Aged, 80 and over
18
2018
6344
0.490
 Why?
Lymphoma, B-Cell
1
2016
86
0.490
 Why?
Prognosis
15
2020
3328
0.480
 Why?
Humans
96
2022
114623
0.470
 Why?
Lymph Nodes
5
2016
419
0.460
 Why?
Aged
36
2019
19061
0.460
 Why?
Proportional Hazards Models
6
2022
1075
0.460
 Why?
Kaplan-Meier Estimate
6
2020
811
0.450
 Why?
Breast Neoplasms, Male
1
2013
28
0.450
 Why?
Neoplasms, Second Primary
3
2020
92
0.440
 Why?
Radiosurgery
2
2019
299
0.430
 Why?
Healthcare Disparities
1
2018
479
0.430
 Why?
BRCA2 Protein
3
2020
41
0.430
 Why?
Radiotherapy Dosage
12
2019
244
0.410
 Why?
Radiotherapy
6
2015
176
0.400
 Why?
Mammaplasty
1
2013
68
0.400
 Why?
Prostatic Neoplasms
4
2022
921
0.400
 Why?
Treatment Outcome
18
2019
9084
0.400
 Why?
Delivery of Health Care
1
2018
833
0.390
 Why?
Follow-Up Studies
10
2017
4411
0.390
 Why?
Survival Analysis
9
2018
1211
0.380
 Why?
Adult
38
2020
30528
0.370
 Why?
BRCA1 Protein
2
2020
56
0.350
 Why?
Whole-Body Irradiation
5
2020
73
0.340
 Why?
Medical Oncology
3
2021
229
0.340
 Why?
Anthracyclines
1
2009
41
0.330
 Why?
Neoplasms, Radiation-Induced
3
2020
67
0.320
 Why?
Sentinel Lymph Node Biopsy
3
2008
99
0.320
 Why?
Antibiotics, Antineoplastic
1
2009
109
0.310
 Why?
United States
16
2019
12176
0.310
 Why?
Cord Blood Stem Cell Transplantation
2
2020
91
0.300
 Why?
Bile Duct Diseases
1
2008
15
0.300
 Why?
Neoplasm Grading
6
2022
242
0.300
 Why?
Leukemia, Lymphocytic, Chronic, B-Cell
3
2017
56
0.300
 Why?
Bile Ducts, Intrahepatic
1
2008
48
0.290
 Why?
Cholestasis, Intrahepatic
1
2008
39
0.290
 Why?
Radiotherapy, Intensity-Modulated
3
2014
124
0.290
 Why?
Thoracic Vertebrae
1
2007
68
0.290
 Why?
Disease-Free Survival
7
2020
620
0.290
 Why?
Prostheses and Implants
1
2007
137
0.270
 Why?
Nutritional Support
1
2006
27
0.260
 Why?
Radiation Oncology
4
2016
75
0.260
 Why?
Heart Diseases
1
2009
331
0.260
 Why?
Transplantation Conditioning
4
2020
151
0.250
 Why?
Survival Rate
8
2019
1644
0.250
 Why?
Graft vs Host Disease
4
2020
212
0.250
 Why?
Receptors, Estrogen
4
2016
372
0.240
 Why?
Male
26
2022
55554
0.240
 Why?
Young Adult
7
2020
10455
0.230
 Why?
Receptor, ErbB-2
4
2019
300
0.220
 Why?
Lymphoma, Non-Hodgkin
2
2014
71
0.220
 Why?
Time Factors
5
2018
6112
0.220
 Why?
Head and Neck Neoplasms
2
2010
427
0.210
 Why?
Trastuzumab
2
2021
89
0.210
 Why?
Flutamide
2
2018
5
0.200
 Why?
Goserelin
2
2018
8
0.200
 Why?
Neoplasm Invasiveness
4
2019
442
0.190
 Why?
Patient Care Planning
2
2021
139
0.190
 Why?
Analysis of Variance
2
2015
1226
0.190
 Why?
Hematopoietic Stem Cell Transplantation
3
2020
520
0.190
 Why?
Bone Neoplasms
2
2018
194
0.190
 Why?
Adenocarcinoma
2
2018
795
0.190
 Why?
Cause of Death
2
2016
361
0.190
 Why?
Survivorship
1
2021
39
0.190
 Why?
Deoxycytidine
1
2022
138
0.190
 Why?
Antibodies, Monoclonal, Humanized
2
2017
663
0.190
 Why?
Tumor Burden
4
2016
259
0.190
 Why?
Androgen Antagonists
2
2022
69
0.180
 Why?
Carcinoma, Squamous Cell
1
2006
577
0.180
 Why?
Clinical Trials as Topic
5
2017
931
0.180
 Why?
Adolescent
9
2020
17831
0.180
 Why?
Neoplasms
2
2011
2097
0.180
 Why?
Azacitidine
1
2021
129
0.180
 Why?
Antineoplastic Agents
7
2017
1879
0.180
 Why?
Antineoplastic Agents, Immunological
2
2019
152
0.180
 Why?
Surgical Instruments
1
2000
47
0.170
 Why?
Radiation Injuries
3
2016
128
0.170
 Why?
Patient Satisfaction
2
2013
578
0.170
 Why?
Practice Guidelines as Topic
5
2017
1394
0.160
 Why?
Randomized Controlled Trials as Topic
8
2022
1214
0.160
 Why?
Vidarabine
3
2018
26
0.160
 Why?
Retrospective Studies
10
2021
12542
0.160
 Why?
Leuprolide
1
2018
19
0.160
 Why?
Aquaporin 4
1
2019
87
0.160
 Why?
Public Health Surveillance
1
2018
61
0.160
 Why?
Thiotepa
1
2018
19
0.150
 Why?
Necrosis
1
2019
211
0.150
 Why?
Diphosphonates
1
2018
51
0.150
 Why?
Rituximab
2
2016
150
0.150
 Why?
Neoadjuvant Therapy
2
2016
304
0.150
 Why?
Leukemia, Myeloid, Acute
2
2021
534
0.150
 Why?
Imidazoles
1
2018
208
0.140
 Why?
Disease Management
2
2018
560
0.140
 Why?
Aromatase Inhibitors
1
2017
49
0.140
 Why?
Chemoradiotherapy
1
2018
188
0.140
 Why?
Patient Care Management
1
2017
53
0.140
 Why?
Lymphoma, Extranodal NK-T-Cell
1
2016
8
0.140
 Why?
Unilateral Breast Neoplasms
1
2016
2
0.140
 Why?
Recurrence
5
2018
935
0.140
 Why?
Margins of Excision
1
2016
29
0.140
 Why?
Multivariate Analysis
3
2009
1430
0.130
 Why?
Lymphoma, T-Cell, Peripheral
1
2016
15
0.130
 Why?
Lymphoma
1
2017
177
0.130
 Why?
Chemotherapy, Adjuvant
6
2017
332
0.130
 Why?
Risk Factors
5
2022
8628
0.130
 Why?
Esthetics
2
2013
37
0.130
 Why?
Datasets as Topic
1
2016
99
0.130
 Why?
Cancer Survivors
1
2019
205
0.130
 Why?
Programmed Cell Death 1 Receptor
1
2017
193
0.130
 Why?
Biopsy
5
2022
1036
0.120
 Why?
Gene Expression Profiling
3
2017
1518
0.120
 Why?
Risk Reduction Behavior
1
2016
201
0.120
 Why?
Gastrointestinal Neoplasms
2
2012
59
0.120
 Why?
Patient Selection
4
2016
641
0.120
 Why?
Propensity Score
1
2016
224
0.120
 Why?
Prostate-Specific Antigen
3
2022
151
0.120
 Why?
Societies, Medical
4
2016
663
0.120
 Why?
Genetic Predisposition to Disease
2
2020
2084
0.120
 Why?
Carcinoma
1
2016
198
0.120
 Why?
Insurance Coverage
1
2016
200
0.120
 Why?
Practice Patterns, Physicians'
3
2017
1177
0.120
 Why?
Palliative Care
2
2018
642
0.110
 Why?
Prospective Studies
8
2022
6217
0.110
 Why?
Triple Negative Breast Neoplasms
1
2016
157
0.110
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2014
82
0.110
 Why?
Beauty
1
2013
11
0.110
 Why?
Receptors, Progesterone
2
2013
319
0.110
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1141
0.110
 Why?
Lymphatic Irradiation
2
2010
9
0.110
 Why?
Diagnostic Self Evaluation
1
2013
22
0.110
 Why?
Axilla
3
2007
39
0.110
 Why?
Lymphatic Metastasis
4
2019
275
0.110
 Why?
Confidence Intervals
1
2013
305
0.110
 Why?
Age Distribution
1
2013
342
0.100
 Why?
Sex Distribution
1
2013
337
0.100
 Why?
Immunotherapy
1
2016
474
0.100
 Why?
Carcinoma, Renal Cell
1
1994
168
0.100
 Why?
Immunosuppressive Agents
3
2006
646
0.100
 Why?
Guideline Adherence
2
2017
490
0.090
 Why?
Cyclophosphamide
2
2009
217
0.090
 Why?
Health Physics
1
2010
4
0.090
 Why?
Lung Neoplasms
2
2018
2177
0.090
 Why?
Antibodies, Monoclonal
1
2017
1262
0.090
 Why?
Doxorubicin
2
2009
285
0.090
 Why?
Four-Dimensional Computed Tomography
1
2010
25
0.090
 Why?
Boronic Acids
1
2010
33
0.090
 Why?
Kidney Neoplasms
1
1994
327
0.080
 Why?
Mutation
1
2020
3344
0.080
 Why?
Clinical Trials, Phase III as Topic
2
2010
82
0.080
 Why?
Pyrazines
1
2010
71
0.080
 Why?
Pregnancy Complications, Neoplastic
1
2009
50
0.080
 Why?
Thrombophilia
1
2009
67
0.080
 Why?
Databases as Topic
1
2008
63
0.080
 Why?
Registries
1
2016
1767
0.080
 Why?
Sex Factors
1
2013
1715
0.080
 Why?
Diagnostic Imaging
1
2010
275
0.080
 Why?
Positron-Emission Tomography
3
2017
259
0.080
 Why?
Iridium Radioisotopes
1
2007
5
0.080
 Why?
Antineoplastic Agents, Hormonal
2
2008
138
0.080
 Why?
Movement
1
2010
244
0.070
 Why?
Comorbidity
3
2017
1448
0.070
 Why?
Incidence
1
2013
2311
0.070
 Why?
Prednisone
1
2008
229
0.070
 Why?
Syndrome
1
2008
333
0.070
 Why?
Age Factors
2
2017
2894
0.070
 Why?
Sternum
1
2006
17
0.070
 Why?
Stomatitis
1
2006
13
0.070
 Why?
Radiology
1
2008
141
0.060
 Why?
Carcinoma, Small Cell
1
2006
158
0.060
 Why?
Mycophenolic Acid
1
2006
77
0.060
 Why?
Carcinoma, Ductal
1
2005
11
0.060
 Why?
Tacrolimus
1
2006
134
0.060
 Why?
Stem Cell Transplantation
1
2006
149
0.060
 Why?
Tomography, X-Ray Computed
3
2009
2279
0.060
 Why?
Reproducibility of Results
5
2012
2762
0.060
 Why?
Magnetic Resonance Imaging
3
2019
3039
0.060
 Why?
Mass Screening
1
2010
1004
0.060
 Why?
Drug Resistance, Neoplasm
2
2019
636
0.060
 Why?
Mastectomy, Modified Radical
2
2000
6
0.060
 Why?
Living Donors
1
2006
270
0.060
 Why?
Anemia, Sideroblastic
1
2003
3
0.060
 Why?
Radiography
2
2010
812
0.050
 Why?
Drug Administration Schedule
2
2018
718
0.050
 Why?
Referral and Consultation
1
2007
632
0.050
 Why?
Child
2
2013
18404
0.050
 Why?
Lymph Node Excision
3
2009
139
0.050
 Why?
Weight Loss
1
2006
641
0.050
 Why?
Professional Staff Committees
1
2001
14
0.050
 Why?
Allografts
1
2021
122
0.050
 Why?
Organ Size
2
2013
434
0.050
 Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2021
172
0.040
 Why?
Automation
1
2020
73
0.040
 Why?
Carcinoma, Lobular
1
2000
44
0.040
 Why?
Germ-Line Mutation
1
2020
130
0.040
 Why?
Salvage Therapy
1
2000
127
0.040
 Why?
Respiration
2
2010
179
0.040
 Why?
Quality Assurance, Health Care
2
2012
311
0.040
 Why?
Risk Management
1
2020
89
0.040
 Why?
Workflow
1
2020
133
0.040
 Why?
Kallikreins
1
2018
30
0.040
 Why?
Fetal Blood
1
2020
270
0.040
 Why?
Myeloablative Agonists
1
2018
21
0.040
 Why?
Sulfonamides
1
2021
445
0.040
 Why?
Genomics
1
2022
635
0.040
 Why?
Maximum Tolerated Dose
2
2010
183
0.040
 Why?
Radiopharmaceuticals
1
2018
157
0.040
 Why?
Osteoblasts
1
2018
106
0.040
 Why?
Canada
1
2018
322
0.040
 Why?
Neutropenia
2
2010
125
0.040
 Why?
Aftercare
1
2019
186
0.040
 Why?
Immunotherapy, Adoptive
1
2019
183
0.040
 Why?
Socioeconomic Factors
2
2017
1077
0.040
 Why?
Retreatment
1
2017
67
0.040
 Why?
Asparaginase
1
2016
31
0.030
 Why?
Ultrasonography
1
2000
633
0.030
 Why?
Fat Necrosis
1
2016
8
0.030
 Why?
Safety
1
2018
297
0.030
 Why?
Metaplasia
1
2016
54
0.030
 Why?
Survivors
1
2019
411
0.030
 Why?
Herpesvirus 4, Human
1
2016
125
0.030
 Why?
Risk Assessment
1
2005
2967
0.030
 Why?
Europe
1
2016
334
0.030
 Why?
North America
1
2016
256
0.030
 Why?
Heart
2
2010
612
0.030
 Why?
Genetic Variation
1
2020
870
0.030
 Why?
Gene Rearrangement
1
2016
135
0.030
 Why?
Postmenopause
2
2009
303
0.030
 Why?
Proto-Oncogene Proteins c-myc
1
2016
115
0.030
 Why?
Immunophenotyping
1
2016
274
0.030
 Why?
Advisory Committees
1
2016
208
0.030
 Why?
Catheterization, Peripheral
1
2016
101
0.030
 Why?
Proto-Oncogene Proteins c-bcl-2
1
2016
213
0.030
 Why?
DNA, Viral
1
2016
350
0.030
 Why?
Clinical Decision-Making
1
2017
268
0.030
 Why?
Radioimmunotherapy
1
2014
11
0.030
 Why?
Odds Ratio
1
2017
953
0.030
 Why?
Child, Preschool
1
2008
9108
0.030
 Why?
Molecular Targeted Therapy
1
2017
347
0.030
 Why?
Actuarial Analysis
1
1994
21
0.030
 Why?
Treatment Failure
1
1994
331
0.030
 Why?
Anti-Bacterial Agents
1
2001
1477
0.030
 Why?
Mass Media
1
2012
37
0.030
 Why?
Brain Neoplasms
1
2019
979
0.020
 Why?
Ultrasonography, Mammary
1
2010
11
0.020
 Why?
Logistic Models
1
2016
1840
0.020
 Why?
Palpation
1
2010
12
0.020
 Why?
Biomarkers, Tumor
1
2017
1040
0.020
 Why?
Thoracic Neoplasms
1
2010
32
0.020
 Why?
Urologic Neoplasms
1
2010
25
0.020
 Why?
Bortezomib
1
2010
41
0.020
 Why?
Prevalence
1
2016
2249
0.020
 Why?
Lymphopenia
1
2010
49
0.020
 Why?
Soft Tissue Neoplasms
1
2010
90
0.020
 Why?
Subcutaneous Fat
1
2010
70
0.020
 Why?
Genital Neoplasms, Female
1
2010
70
0.020
 Why?
Radiation Dosage
1
2010
132
0.020
 Why?
Nausea
1
2010
101
0.020
 Why?
Longitudinal Studies
1
2016
2387
0.020
 Why?
Pregnancy Trimester, Second
1
2009
66
0.020
 Why?
Statistics, Nonparametric
1
2010
385
0.020
 Why?
Infusions, Intravenous
1
2010
371
0.020
 Why?
Diarrhea
1
2010
171
0.020
 Why?
Pregnancy Trimester, First
1
2009
125
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
171
0.020
 Why?
Premenopause
1
2009
106
0.020
 Why?
Calcinosis
1
2010
242
0.020
 Why?
Observer Variation
1
2009
295
0.020
 Why?
Fatigue
1
2010
294
0.020
 Why?
Credentialing
1
2007
12
0.020
 Why?
Perimenopause
1
2008
61
0.020
 Why?
Algorithms
1
2015
1466
0.020
 Why?
Fibrosis
1
2010
453
0.020
 Why?
Quality Control
1
2008
144
0.020
 Why?
Quality of Life
1
2018
2353
0.020
 Why?
In Situ Hybridization, Fluorescence
1
2008
309
0.020
 Why?
Medicare
1
2012
665
0.020
 Why?
Lung
2
2010
3558
0.020
 Why?
Biomarkers
1
2016
3408
0.020
 Why?
Evidence-Based Medicine
1
2010
668
0.020
 Why?
Diagnosis, Differential
1
2010
1342
0.020
 Why?
Benchmarking
1
2007
161
0.020
 Why?
Signal Transduction
1
2019
4509
0.020
 Why?
Colorado
2
2010
4099
0.020
 Why?
Taxoids
1
2006
93
0.020
 Why?
Etoposide
1
2006
148
0.020
 Why?
Carboplatin
1
2006
135
0.020
 Why?
Dose-Response Relationship, Drug
1
2010
1842
0.020
 Why?
Genital Diseases, Male
1
1985
15
0.020
 Why?
Chlamydia trachomatis
1
1985
36
0.020
 Why?
Genital Diseases, Female
1
1985
25
0.020
 Why?
Pharynx
1
1985
49
0.020
 Why?
Siblings
1
2006
221
0.020
 Why?
Feasibility Studies
1
2007
739
0.010
 Why?
Cisplatin
1
2006
262
0.010
 Why?
Neoplasm Proteins
1
2007
384
0.010
 Why?
Immunohistochemistry
1
2008
1629
0.010
 Why?
Hematologic Neoplasms
1
2006
137
0.010
 Why?
Rectum
1
1985
153
0.010
 Why?
Antilymphocyte Serum
1
2003
60
0.010
 Why?
Sexually Transmitted Diseases
1
1985
155
0.010
 Why?
Graft Rejection
1
2006
513
0.010
 Why?
Fatal Outcome
1
2003
284
0.010
 Why?
Transplantation, Homologous
1
2003
377
0.010
 Why?
Skin Neoplasms
1
2009
756
0.010
 Why?
Transplantation, Heterologous
1
2001
181
0.010
 Why?
Organizational Objectives
1
2001
66
0.010
 Why?
Hospitals, Private
1
1999
11
0.010
 Why?
Hospitals, County
1
1999
10
0.010
 Why?
Hospitals, University
1
1999
172
0.010
 Why?
Forecasting
1
2001
330
0.010
 Why?
Infant, Newborn
1
2009
5043
0.010
 Why?
Reoperation
1
2000
514
0.010
 Why?
Pregnancy
1
2009
5517
0.010
 Why?
Patient Education as Topic
1
1999
680
0.010
 Why?
Bacteriological Techniques
1
1985
65
0.000
 Why?
Chlamydia Infections
1
1985
65
0.000
 Why?
Risk
1
1985
812
0.000
 Why?
Sexual Behavior
1
1985
440
0.000
 Why?
Rabinovitch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (341) concept(s)
_
Co-Authors Expand Description
See all (38) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)